Abstract
There are many registries in Latin America as dialysis and kidney transplantation, breast cancer, primary immunodeficiency, acute coronary syndromes, but the focus here are the registries of lysosomal storage diseases (LSD) because is our experience. Registry of Gaucher disease, Fabry disease, Pompe disease, and mucopolysaccharidosis type I are comprehensive observational voluntary programs that aim to collect clinical and laboratory data of initiation, progression, and evolution of those diseases, with and without treatment, using questionnaires of quality of life and/or skills and functions. There are two more programs of LSD: Hunter outcome survey and Fabry outcome survey. The registries are a kind of phase IV clinical trials, postmarketing studies delineate additional information including the drug’s risks, benefits, and optimal use, and in addition we have data from natural history. The demographics of the Gaucher, Fabry, MPS I, and Pompe Registries show that a total of patients, being 16%, 8%, 15%, and 7%, respectively, of this population, and 19%, 19%, 18%, and 13%, respectively, of all physicians participating in the program are from Latin America. In the Gaucher Registry, we can observe that the percentage of children in Latin America (29%) is bigger than the rest of the world (20%), what can mean more severe disease in this population. These diseases are rare, and a database of clinical data from a larger number of patients gives us the opportunity to know about the natural history of these diseases, their phenotypic variability, and the response to specific enzyme replacement therapy in our population.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sims K, Lee P, Wilcox W, Wanner C, Martins AM (2009) Fabry Registry Annual Report 2009. Published by Genzyme Corporation. http://www.fabry.org/fsig.psf/PDFs/PDFsR/$File/2009_RADAR.pdf
Sobreira E, Pires RF, Cizmarik M, Grabowski GA (2007) Phenotypic and genotypic heterogeneity in Gaucher disease type 1: a comparison between Brazil and the rest-of-the-world. Mol Genet Metab 90:81–86
Thadani R (2006) Formal trials versus observational studies. In: Metha A, Beck M, Sunder-Plassmann G (eds) Fabry disease, perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford. http://www.ncbi.nlm.nih.gov/bookshelf/
Acknowledgments
The authors would like to thank Genzyme Corporation, Genzyme do Brasil, ICGG Gaucher Registry, Fabry Registry, MPS I Registry, Pompe Registry, to their support and the physicians and patients to their participation in the registries.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Martins, A.M. et al. (2011). Utility of Rare Disease Registries in Latin America. In: JIMD Reports - Case and Research Reports, 2011/1. JIMD Reports, vol 1. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2011_25
Download citation
DOI: https://doi.org/10.1007/8904_2011_25
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-17707-1
Online ISBN: 978-3-642-17708-8
eBook Packages: MedicineMedicine (R0)